Literature DB >> 29549536

Predictive factors in patients eligible for pegfilgrastim prophylaxis focusing on RDI using ordered logistic regression analysis.

Yuko Kanbayashi1,2,3, Takeshi Ishikawa4,5, Motohiro Kanazawa4,6, Yuki Nakajima7,4, Rumi Kawano4,8, Yusuke Tabuchi7, Tomoko Yoshioka4,9,8, Norihiko Ihara7,4, Toyoshi Hosokawa9,10, Koichi Takayama11, Keisuke Shikata7, Tetsuya Taguchi4,12.   

Abstract

Although pegfilgrastim prophylaxis is expected to maintain the relative dose intensity (RDI) of chemotherapy and improve safety, information is limited. However, the optimal selection of patients eligible for pegfilgrastim prophylaxis is an important issue from a medical economics viewpoint. Therefore, this retrospective study identified factors that could predict these eligible patients to maintain the RDI. The participants included 166 cancer patients undergoing pegfilgrastim prophylaxis combined with chemotherapy in our outpatient chemotherapy center between March 2015 and April 2017. Variables were extracted from clinical records for regression analysis of factors related to maintenance of the RDI. RDI was classified into four categories: 100% = 0, 85% or < 100% = 1, 60% or < 85% = 2, and < 60% = 3. Multivariate ordered logistic regression analysis was performed to identify predictive factors in patients eligible for pegfilgrastim prophylaxis to maintain the RDI. Threshold measures were examined using a receiver operating characteristic (ROC) analysis curve. Age [odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04-1.11; P < 0.0001], anemia (grade) (OR 1.77, 95% CI 1.10-2.84; P = 0.0184), and administration 24-72 h after chemotherapy (OR 0.44, 95% CI 0.22-0.89; P = 0.0224) were factors that significantly correlated with RDI maintenance. ROC curve analysis of the group that failed to maintain the RDI indicated that the threshold for age was 70 years and above, with a sensitivity of 60.0% and specificity of 80.2% (area under the curve: 0.74). In conclusion, younger age, anemia (less), and administration of pegfilgrastim 24-72 h after chemotherapy were significant factors for RDI maintenance.

Entities:  

Keywords:  24–72 h; Age; Anemia; Pegfilgrastim; RDI

Mesh:

Substances:

Year:  2018        PMID: 29549536     DOI: 10.1007/s12032-018-1116-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications.

Authors:  J Crawford; C Caserta; F Roila
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Astemizole in the treatment of granulocyte colony-stimulating factor-induced bone pain.

Authors:  R Gudi; M Krishnamurthy; B R Pachter
Journal:  Ann Intern Med       Date:  1995-08-01       Impact factor: 25.391

3.  Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

Authors:  Jeffrey J Kirshner; Charles E Heckler; Michelle C Janelsins; Shaker R Dakhil; Judith O Hopkins; Charlotte Coles; Gary R Morrow
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

4.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.

Authors:  G Bonadonna; P Valagussa; A Moliterni; M Zambetti; C Brambilla
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

5.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Authors:  Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher
Journal:  J Clin Oncol       Date:  2004-09-20       Impact factor: 44.544

6.  The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.

Authors:  Jenny M Whitworth; Kellie S Matthews; Kimberly A Shipman; T Michael Numnum; James E Kendrick; Larry C Kilgore; J Michael Straughn
Journal:  Gynecol Oncol       Date:  2008-12-24       Impact factor: 5.482

Review 7.  Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

Authors:  Yassine Lalami; Jean Klastersky
Journal:  Crit Rev Oncol Hematol       Date:  2017-11-11       Impact factor: 6.312

Review 8.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

Review 9.  The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Authors:  G H Lyman; D C Dale; E Culakova; M S Poniewierski; D A Wolff; N M Kuderer; M Huang; J Crawford
Journal:  Ann Oncol       Date:  2013-06-20       Impact factor: 32.976

10.  Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

Authors:  Derek Weycker; Xiaoyan Li; Jacqueline Figueredo; Rich Barron; Spiros Tzivelekis; May Hagiwara
Journal:  Support Care Cancer       Date:  2015-11-25       Impact factor: 3.359

View more
  1 in total

1.  Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer.

Authors:  Kenro Chikazawa; Ken Imai; Takaki Ito; Azusa Kimura; K O Hiroyoshi; Yokota Miho; Tomoyuki Kuwata; Ryo Konno
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.